Zydus Lifesciences
Biosimilar developer, India. 11 development products across 11 molecules: adalimumab, aflibercept, bevacizumab, epoetin alfa and zeta, follitropin alfa, interferon alfa-2b, pertuzumab, ranibizumab, rituximab, teriparatide, trastuzumab.
First approval in the Atlas: Apr 2010, Cadila Healthcare (INN only), epoetin alfa and zeta (CDSCO)
FDAproducts approved1
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved10
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Exemptia / Cadalimab ZRC-3197 | · | · | · | · | Sep 2014 | · |
| Aflibercept | Zydus aflibercept | · | · | · | · | Jun 2025 | · |
| Bevacizumab | Zydus bevacizumab | · | · | · | · | May 2017 | · |
| Epoetin alfa and zeta | Zydus epoetin | · | · | · | · | Apr 2010 | · |
| Follitropin alfa | Zydus follitropin alfa | · | · | · | · | Jan 2018 | · |
| Interferon alfa-2b | Zydus peginterferon alfa-2b | · | · | · | · | Jun 2011 | · |
| Pertuzumab | Zydus pertuzumab | · | · | · | · | Apr 2024 | · |
| Ranibizumab | Nufymco | Dec 2025 | · | · | · | · | · |
| Rituximab | Zydus rituximab | · | · | · | · | Jun 2025 | · |
| Teriparatide | Zydus teriparatide | · | · | · | · | Aug 2012 | · |
| Trastuzumab | Zydus trastuzumab | · | · | · | · | Oct 2015 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOApr 2010Cadila Healthcare (INN only), epoetin alfa and zeta
- CDSCOJun 2011Cadila Healthcare (INN only), interferon alfa-2b
- CDSCOAug 2012Cadila Healthcare (INN only), teriparatide
- CDSCOSep 2014Exemptia, adalimumab
- CDSCOOct 2015Cadila Healthcare (INN only), trastuzumab
- CDSCOMay 2017Cadila Healthcare (INN only), bevacizumab
- CDSCOJan 2018Cadila Healthcare (INN only), follitropin alfa
- CDSCOApr 2024Zydus Lifesciences (INN only), pertuzumab
- CDSCOJun 2025Zydus Lifesciences (INN only), aflibercept
- CDSCOJun 2025Zydus Lifesciences (INN only), rituximab
- FDADec 2025Nufymco, ranibizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.